The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke
Abstract
Background and Purpose We sought to identify variables associated with intracerebral hemorrhage in patients with acute ischemic stroke who receive tissue plasminogen activator (t-PA). Methods We performed subgroup analyses of data from a randomized, double-blind, placebo-controlled trial of intravenous t-PA administered to stroke patients within 3 hours of onset. Using multivariable regression modeling procedures, we assessed the relationship of baseline and after-treatment variables with symptomatic and asymptomatic intracerebral hemorrhage during the first 36 hours after treatment. Results Overall, t-PA–treated patients had an increase in the absolute risk of symptomatic intracerebral hemorrhage of 6% and a decrease in the absolute risk of 3-month mortality of 4% compared with placebo-treated patients. The only variables independently associated with an increased risk of symptomatic intracerebral hemorrhage in the final multivariable logistic regression model for the 312 t-PA–treated patients were the severity of neurological deficit as measured by the National Institutes of Health Stroke Scale score (five categories; odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2 to 2.9) and brain edema (defined as acute hypodensity) or mass effect by CT before treatment (OR, 7.8; 95% CI, 2.2 to 27.1). This final model correctly predicted those t-PA–treated patients who would or would not have a symptomatic hemorrhage with only 57% efficiency. In the subgroup of patients with a severe neurological deficit, t-PA–treated patients were more likely than placebo-treated patients to have a favorable 3-month outcome (adjusted OR based on multiple outcomes, 4.3; 95% CI, 1.6 to 11.9). These results were similar for the subgroup with edema or mass effect by CT (adjusted OR, 3.4; 95% CI, 0.6 to 20.7). The likelihood of severe disability or death was similar for t-PA–and placebo-treated patients with these two baseline characteristics. Conclusions Despite a higher rate of intracerebral hemorrhage, patients with severe strokes or edema or mass effect on the baseline CT are reasonable candidates for t-PA, if it is administered within 3 hours of onset.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Self-citationBeneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis
(1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250701 · Cited by 8,368
ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale
JENNETT, B. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92830-5 · Cited by 7,501
Best Subsets Logistic Regression
Hosmer, D. W., Jovanovic, B., & Lemeshow, S. (1989) · Biometrics · doi:10.2307/2531779 · Cited by 1,176
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
del Zoppo, G. J., Poeck, K., Pessin, M. S., Wolpert, S. M., Furlan, A. J., Ferbert, A., Alberts, M. J., Zivin, J. A., Wechsler, L., Busse, O., et al. (1992) · Annals of Neurology · doi:10.1002/ana.410320113 · Cited by 999
Mahoney, F. I., & Barthel, D. W. (2013) · PsycTESTS Dataset · doi:10.1037/t02366-000 · Cited by 887
Multicentre Acute Stroke Trial—Italy (MAST-I) Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92049-8 · Cited by 633
Regression, Prediction and Shrinkage
Copas, J. B. (1983) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1983.tb01258.x · Cited by 612
Thrombolytic Therapy with Streptokinase in Acute Ischemic Stroke
(1996) · New England Journal of Medicine · doi:10.1056/nejm199607183350301 · Cited by 570
Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
Simoons, M. L., de Jaegere, P. P. T., van Domburg, R., Boersma, E. H., Maggioni, A. P., Mg, F., Leimberger, J., Califf, R. M., Schröder, R., Knatterud, G. L., et al. (1993) · The Lancet · doi:10.1016/s0140-6736(05)80089-3 · Cited by 296
Trials of streptokinase in severe acute ischaemic stroke
Shahar, E., McGovern, P., Hommel, M., Pierre Boissel, J., Donnan, G., Davis, S., Chambers, B., Gates, P., Hankey, G., McNeil, J., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90484-0 · Cited by 188
Tissue-Type Plasminogen Activator Should Not Be Used in Acute Ischemic Stroke
Riggs, J. E. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550120118026 · Cited by 26
Interpretation of Subgroup Analyses in Clinical Trials
Fleming, T. R. (1995) · Drug Information Journal · doi:10.1177/00928615950290s114 · Cited by 19
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684
Barber, P. A., Demchuk, A. M., Zhang, J., & Buchan, A. M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02237-6 · Cited by 2,668
(2004) · The Lancet · doi:10.1016/s0140-6736(04)15692-4 · Cited by 2,557
von Kummer, R., Broderick, J. P., Campbell, B. C. V., Demchuk, A., Goyal, M., Hill, M. D., Treurniet, K. M., Majoie, C. B. L. M., Marquering, H. A., Mazya, M. V., et al. (2015) · Stroke · doi:10.1161/strokeaha.115.010049 · Cited by 1,409
Metadata
- Authors
- The NINDS t-PA Stroke Study Group
- Venue
- Stroke
- Published
- 1997-11
- Volume
- 28
- Issue
- 11
- Pages
- 2109-2118
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W4250104750
- Cited by
- 880
- References
- 14
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.